Case report: Progressive pulmonary artery hypertension in a case of megalencephaly-capillary malformation syndrome

Front Genet. 2023 Aug 8:14:1221745. doi: 10.3389/fgene.2023.1221745. eCollection 2023.

Abstract

Megalencephaly-capillary malformation syndrome (MCAP, OMIM # 602501) is caused by hyperactivity of the thephosphoinositide-3-kinase (PI3K)-Vakt murine thymoma viral oncogene homolog (AKT)-mammalian target of rapamycin (mTOR) pathway, which results in megalencephaly, capillary malformations, asymmetrical overgrowth, and connective tissue dysplasia. Herein, we report the case of a 7-month-old girl with MCAP due to a PIK3CA somatic mosaic variant who presented with atrial tachycardia, finally diagnosed as pulmonary arterial hypertension (PAH). Oxygen therapy and sildenafil decreased pulmonary blood pressure and improved atrial tachycardia. Previous studies reported an association between the PI3K/AKT/mTOR pathway and abnormal pulmonary arterial smooth muscle cell proliferation, which may be associated with PAH. PAH should be considered a potentially lethal complication in MCAP patients, even when no structural cardiac abnormalities are identified in the neonatal period.

Keywords: PI3K/Akt/mTOR pathway; PIK3CA; megalencephaly-capillary malformation syndrome; overgrowth syndrome; pulmonary arterial hypertension.

Publication types

  • Case Reports

Grants and funding

This study was supported by the Japan Society for the Promotion of Science (grant nos. JP16H05160, JP16K09975, JP20K08236, and JP21K07694), MHLW Research programs on rare and intractable diseases (JPMH20FC1039 and JPMH20FC1046), and an HUSM Grant-in-Aid from Hamamatsu University School of Medicine.